Frank Harder
Keine laufenden Positionen mehr
Profil
Frank Harder formerly worked at Bioporto A, as Chief Financial Officer & IR Contact from 2007 to 2014, Zymenex A, as Chief Financial Officer, and PhaseOneTrials A, as Chief Financial Officer.
Mr. Harder received his graduate degree from the University of Copenhagen.
Ehemalige bekannte Positionen von Frank Harder
| Unternehmen | Position | Ende |
|---|---|---|
| BIOPORTO A/S | Finanzdirektor/CFO | 01.01.2014 |
Zymenex A/S
 Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Finanzdirektor/CFO | - |
PhaseOneTrials A/S
 PhaseOneTrials A/S Miscellaneous Commercial ServicesCommercial Services PhaseOneTrials A/S is a Danish Contract Research Organization (CRO) that conducts clinical phase I trials and early phase II trials of new drug candidates. Phase I trials include studies in which a new drug is tested for the first time in healthy humans – also known as “First-in-Man” studies. Early phase II studies, or “Proof-of-Concept” studies, include testing a drug in small groups of patients to determine whether the drug has the desired effects on a given disease. | Finanzdirektor/CFO | - |
Ausbildung von Frank Harder
| University of Copenhagen | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOPORTO A/S | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Zymenex A/S
Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Health Technology |
PhaseOneTrials A/S
PhaseOneTrials A/S Miscellaneous Commercial ServicesCommercial Services PhaseOneTrials A/S is a Danish Contract Research Organization (CRO) that conducts clinical phase I trials and early phase II trials of new drug candidates. Phase I trials include studies in which a new drug is tested for the first time in healthy humans – also known as “First-in-Man” studies. Early phase II studies, or “Proof-of-Concept” studies, include testing a drug in small groups of patients to determine whether the drug has the desired effects on a given disease. | Commercial Services |
